Researchers at the Sanford Stem Cell Institute have taken the fight against rare diseases to the lab, to patients’ bedsides ...

February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the world's first person to receive a personalized CRISPR-based gene ...

On the occasion of this Rare Disease Day, Mstone Partners Healthcare and our portfolio companies are proud to stand with the ...

Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen ...

Creative Diagnostics announces the launch of Products for Renal Metabolism. NEW YORK, NY, UNITED STATES, February 10, ...

LOARGYS is the first and only therapy proven to lower arginine in patients 2 years of age and older living with ARG1-D -- ARG1-D is an ultra-rare, debilitating, and progressive metabolic disease ...

WASHINGTON - The Food and Drug Administration on Monday introduced a regulatory pathway aimed at accelerating the development of drugs for ultra-rare diseases, providing new hope, in particular, to ...

For more than six decades, biomarker-based newborn screening has played a pivotal role in reducing infant mortality and long-term disability by enabling early detection of metabolic and endocrine ...

CF Industries' low-cost structure provides a durable competitive edge in volatile commodity cycles. Read more on CF stock here.

CVR Partners plants are now operating normally after excessive Q4 downtime, driven by third-party air separation unit issues ...

Living off of juice for a week won’t flush out harmful substances—it’ll just make you hangry.

India used the India AI Impact Summit in New Delhi this week to signal both its ambition and growing capability in shaping global artificial intelligence (AI) rules. Despite a few organizational ...